Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 阳光诺和是一家专注于仿制和创新药物研究，致力于以技术服务为核心，推动中国医药行业发展，为客户提供「临床前+临床」全过程药物研发服务的综合型CRO公司，成立于2009年3月9日，位于北京市昌平区双营西路79号云谷园7、29、30号楼，服务中国医药，成为领先的医药研发专家，是诺和人一直追求的目标。阳光诺和从药物发现、到化学药物、多肽药物研发，再到临床研究资源的整合，生物样本检测团队的构建，寻找到了最佳的契合点，成功打造了全过程CRO服务模式。公司凭借优秀稳定的研发团队，建立健全的质量检测和控制体系，匹配最新的药物研发法规要求，确保高效合规为客户提供品质卓越的技术服务。北京阳光诺和药物研究股份有限公司为国家高新技术企业、中关村高新技术企业、北京医药行业协会常务理事单位，于2017年10月率先在药学研发机构通过ISO9001:2015质量管理体系、ISO14001:2015环境管理体系、OHSAS18001：2007职业健康安全管理体系（三合一管理体系）认证，2017年度、2018年度、2019年度公司连续获得中华全国工商业联合会医药业商会授予的“中国医药研发公司20强”称号，曾获得北京市博士后创新实践工作站，北京市级科技研究开发机构等众多荣誉。阳光诺和拥有近10000平米实验区，配备国际一流仪器设备。公司具有领先的化学药物和多肽药物的研发实力，努力成为CMC研究的行业典范。在药学领域，临床CRO研究和药代分析与评价领域拥有优秀的研发团队，由经验丰富的技术专家领衔。
Main Business 对医药企业提供研发外包服务，涉及仿制药开发、一致性评价及新药开发等。
Legal Representative 刘宇晶
Top Executives
董事长：利虔
董事：李文然,赵凌阳,刘宇晶,张颖,陈巧
独立董事：何壮坤,朱慧婷,时现
Top 5 Shareholder
Shareholder name Nature Holding Date
利虔流通A股27.59%30/06/2024
刘宇晶流通A股5.42%30/06/2024
中国工商银行股份有限公司－富国天惠精选成长混合型证券投资基金（LOF）流通A股4.46%30/06/2024
基本养老保险基金一六零二二组合流通A股3.35%30/06/2024
中国工商银行股份有限公司－融通健康产业灵活配置混合型证券投资基金流通A股3.19%30/06/2024
Company Secretary 赵凌阳
Solicitors 北京市天元律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 010-60748199
Fax No 010-60748199
Website www.sun-novo.com
Email ir@sun-novo.com
Company Address
Register: 北京市昌平区科技园区双营西路79号院7号楼一层
Office: 北京市昌平区科技园区双营西路79号院7号楼一层
Listing Date 21/06/2021
Shares Capital
Shares Capital: 112,000,000
Total A Share: 112,000,000
Listed A Share: 112,000,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.650
DPS(RMB)* ¥ 0.165
NBV Per Share(RMB)* ¥ 9.286
Market Capitalization(RMB) 3.282B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.